PER 0.00% 10.5¢ percheron therapeutics limited

“Long Neuro COVID-19 is hypothesized to follow SARS-CoV-2 virus...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 13,371 Posts.
    lightbulb Created with Sketch. 1436
    “Long Neuro COVID-19 is hypothesized to follow SARS-CoV-2 virus specific pathophysiological changes, with aberrant inflammatory disease and immune responses post-acute infection, similar to that reported with other viral infections including Epstein-Barr Virus (EBV) and associated Chronic Fatigue Syndrome2. Notably patients who had COVID-19 while also infected with EBV were at an increased risk of memory loss7 and EBV infection increases the risk of autoimmune diseases such as Multiple Sclerosis (MS)8 and associated adverse neurological manifestations. ANP’s immunomodulatory drug ATL1102 has previously demonstrated biologic activity in MS patients…”

    Itsa :No brainer..

 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.000(0.00%)
Mkt cap ! $94.66M
Open High Low Value Volume
11.0¢ 11.0¢ 10.0¢ $50.72K 487.1K

Buyers (Bids)

No. Vol. Price($)
12 471705 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 22797 3
View Market Depth
Last trade - 11.56am 01/10/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.